K. B. Nolop

23.8k total citations · 4 hit papers
64 papers, 7.3k citations indexed

About

K. B. Nolop is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, K. B. Nolop has authored 64 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 20 papers in Pulmonary and Respiratory Medicine and 18 papers in Oncology. Recurrent topics in K. B. Nolop's work include Melanoma and MAPK Pathways (21 papers), Asthma and respiratory diseases (15 papers) and Allergic Rhinitis and Sensitization (9 papers). K. B. Nolop is often cited by papers focused on Melanoma and MAPK Pathways (21 papers), Asthma and respiratory diseases (15 papers) and Allergic Rhinitis and Sensitization (9 papers). K. B. Nolop collaborates with scholars based in United States, Australia and United Kingdom. K. B. Nolop's co-authors include Grant A. McArthur, Keith T. Flaherty, Igor Puzanov, Paul B. Chapman, Antoni Ribas, Jeffrey A. Sosman, Richard J. Lee, Kevin B. Kim, Peter J. O’Dwyer and Joseph F. Grippo and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

K. B. Nolop

64 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 2.6k citations Keith T. Flaherty, Igor Puzanov et al. profile →
Vemurafenib: the first drug approved for BRAF-mutant cancer

2012 594 citations Gideon Bollag, James Tsai et al. Nature Reviews Drug Discovery profile →
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

2015 513 citations Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology profile →
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

2015 433 citations Nicholas Butowski, Howard Colman et al. Neuro-Oncology profile →

Peers

K. B. Nolop

ONCOL

PRM

PHYSI

Ronit Simantov United States

Graham J. Mann Australia

Stephen F. Madden Ireland

George M. Yousef Canada

Eliot M. Rosen United States

Dilip D. Giri United States

Linda T. Vahdat United States

Mark M. Moasser United States

Carlo Palmieri United Kingdom

Teppei Morikawa Japan

Ronit Simantov United States

K. B. Nolop

5.5k ×1.5

3.3k ×1.0

ONCOL

4.3k ×2.8

PRM

409 ×0.4

PHYSI

2.6k ×2.9

Citations per year, relative to K. B. Nolop K. B. Nolop (= 1×) peers Ronit Simantov

Countries citing papers authored by K. B. Nolop

Since Specialization

Citations

This map shows the geographic impact of K. B. Nolop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. B. Nolop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. B. Nolop more than expected).

Fields of papers citing papers by K. B. Nolop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. B. Nolop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. B. Nolop. The network helps show where K. B. Nolop may publish in the future.

Co-authorship network of co-authors of K. B. Nolop

This figure shows the co-authorship network connecting the top 25 collaborators of K. B. Nolop. A scholar is included among the top collaborators of K. B. Nolop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. B. Nolop. K. B. Nolop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kopetz, Scott, Jayesh Desai, Emily Chan, et al.. (2015). Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer. Journal of Clinical Oncology. 33(34). 4032–4038. 513 indexed citations breakdown →

Butowski, Nicholas, Howard Colman, John de Groot, et al.. (2015). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology. 18(4). 557–564. 433 indexed citations breakdown →

Puzanov, Igor, Ravi K. Amaravadi, Grant A. McArthur, et al.. (2015). Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer. 51(11). 1435–1443. 52 indexed citations

Kim, Kevin B., Maria E. Cabanillas, Alexander J. Lazar, et al.. (2013). Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF ^V600E Mutation. Thyroid. 23(10). 1277–1283. 157 indexed citations

Bollag, Gideon, James Tsai, Jiazhong Zhang, et al.. (2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews Drug Discovery. 11(11). 873–886. 594 indexed citations breakdown →

Tie, Jeanne, Peter Gibbs, Lara Lipton, et al.. (2010). Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF^V600E mutation. International Journal of Cancer. 128(9). 2075–2084. 182 indexed citations

Flaherty, Keith T., Igor Puzanov, Jeffrey A. Sosman, et al.. (2009). Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. Journal of Clinical Oncology. 27(15_suppl). 9000–9000. 163 indexed citations

Noonan, Michael, Jill P. Karpel, George Bensch, et al.. (2001). Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Annals of Allergy Asthma & Immunology. 86(1). 36–43. 78 indexed citations

Nathan, Robert A., Anjuli Nayak, David F. Graft, et al.. (2001). Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Annals of Allergy Asthma & Immunology. 86(2). 203–210. 44 indexed citations

10.

Kemp, James P., Robert Berkowitz, S. David Miller, et al.. (2000). Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. Journal of Allergy and Clinical Immunology. 106(3). 485–492. 70 indexed citations

11.

Frieri, Marianne, et al.. (1998). Effect of Mometasone Furoate on Early and Late Phase Inflammation in Patients with Seasonal Allergic Rhinitis. Annals of Allergy Asthma & Immunology. 81(5). 431–437. 36 indexed citations

12.

Ware, John E., James P. Kemp, David A. Buchner, et al.. (1998). The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults.. Quality of Life Research. 7(3). 235–244. 82 indexed citations

13.

Nathan, Robert A., K. B. Nolop, Francis M. Cuss, & Richard Lorber. (1997). A Comparison of Double-Strength Beclomethasone Dipropionate (84 μg) MDI With Beclomethasone Dipropionate (42 μ) MDI in the Treatment of Asthma. CHEST Journal. 112(1). 34–39. 16 indexed citations

14.

Mandl, Michael, K. B. Nolop, & Barry N. Lutsky. (1997). Comparison of Once Daily Mometasone Furoate (Nasonex) and Fluticasone Propionate Aqueous Nasal Sprays for the Treatment of Perennial Rhinitis. Annals of Allergy Asthma & Immunology. 79(4). 370–378. 78 indexed citations

15.

Bronsky, Edwin A., Donald W. Aaronson, Robert Berkowitz, et al.. (1997). Dose Ranging Study of Mometasone Furoate (Nasonex) in Seasonal Allergic Rhinitis. Annals of Allergy Asthma & Immunology. 79(1). 51–56. 55 indexed citations

16.

Hébert, Jacques, K. B. Nolop, & Barry N. Lutsky. (1996). Once‐daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐ and placebo‐controlled study. Allergy. 51(8). 569–576. 74 indexed citations

17.

Ryan, Una, Marilyn K. Glassberg, & K. B. Nolop. (1989). Endothelin-1 from Pulmonary Artery and Micro vessels Acts on Vascular and Airway Smooth Muscle. Journal of Cardiovascular Pharmacology. 13. S57–62. 21 indexed citations

18.

Nolop, K. B., Lars Brudin, R. P. Beaney, et al.. (1987). Glucose utilizationin vivo by human pulmonary neoplasms. Cancer. 60(11). 2682–2689. 214 indexed citations

19.

Nolop, K. B., et al.. (1987). A Comparison of ^99m Tc-DTPA and ^113m In-DTPA Aerosol Clearances in Humans: Effects of Smoking, Hyperinflation, and in vitro Oxidation. American Review of Respiratory Disease. 136(5). 1112–1116. 26 indexed citations

20.

Braude, S., K. B. Nolop, John Fleming, et al.. (1986). Increased Pulmonary Transvascular Protein Flux after Canine Cardiopulmonary Bypass. American Review of Respiratory Disease. 134(5). 867–872. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact